Lista de obras -

A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions?

artículo científico publicado en 2009

A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.

artículo científico publicado en 2012

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.

artículo científico publicado en 2010

A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.

artículo científico publicado en 2010

Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation

artículo científico publicado en 2007

Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox

artículo científico publicado en 2005

Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.

artículo científico publicado en 2017

Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance

artículo científico publicado en 2015

Application of liquid biopsies to identify genomic factors associated with therapy resistance in castration resistant prostate cancer.

artículo científico publicado en 2016

Arrays of High-Aspect Ratio Microchannels for High-Throughput Isolation of Circulating Tumor Cells (CTCs).

artículo científico publicado en 2014

Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints

artículo científico publicado en 2018

Cistrome analysis of YY1 uncovers a regulatory axis of YY1:BRD2/4-PFKP during tumorigenesis of advanced prostate cancer

artículo científico publicado en 2021

Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series

scientific article published on 08 January 2019

Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase

artículo científico publicado en 2019

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases

artículo científico publicado en 2010

Functional role for the c-Abl tyrosine kinase in meiosis I

scientific journal article

Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps

artículo científico publicado en 2015

Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium

artículo científico publicado en 2019

Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.

artículo científico publicado en 2005

Identification of a pseudogene that can masquerade as a mutant allele of the PTEN/MMAC1 tumor suppressor gene.

artículo científico publicado en 1998

Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression ⬇️

artículo científico publicado el 28 de abril de 1998

Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.

artículo científico publicado en 2005

Interaction between androgen receptor and coregulator SLIRP is regulated by Ack1 tyrosine kinase and androgen

scientific article published on 09 December 2019

Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability

artículo científico publicado en 2006

Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer.

artículo científico publicado en 2014

Mutation of androgen receptor N-terminal phosphorylation site Tyr-267 leads to inhibition of nuclear translocation and DNA binding

artículo científico publicado en 2015

Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings

artículo científico publicado en 2015

Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial

scientific article published on 21 December 2009

PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway.

artículo científico publicado en 2002

Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer

artículo científico publicado en 2012

Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy

scientific article published on 08 October 2018

Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancer.

artículo científico publicado en 2014

Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC

artículo científico publicado en 2020

Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment.

artículo científico publicado en 2010

Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest.

artículo científico publicado en 2005

Regulation of sensitivity to TRAIL by the PTEN tumor suppressor.

artículo científico publicado en 2004

Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase

artículo científico publicado en 2000

Renal cell carcinoma

artículo científico publicado en 2003

Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer

artículo científico publicado en 2011

Role for c-Abl tyrosine kinase in growth arrest response to DNA damage.

artículo científico publicado en 1996

Signal transduction by wild-type and leukemogenic Abl proteins.

artículo científico publicado en 1997

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.

artículo científico publicado en 2017

The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels.

artículo científico publicado en 2005

The impact of altered annexin I protein levels on apoptosis and signal transduction pathways in prostate cancer cells.

artículo científico publicado en 2006

ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer

artículo científico publicado en 2018

Zinc-induced PTEN protein degradation through the proteasome pathway in human airway epithelial cells.

artículo científico publicado en 2003

c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency

scientific journal article

p38 and EGF receptor kinase-mediated activation of the phosphatidylinositol 3-kinase/Akt pathway is required for Zn2+-induced cyclooxygenase-2 expression.

artículo científico publicado en 2005

Lista de obras de

A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions?

A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.

A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.

Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation

Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox

Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.

Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance

Application of liquid biopsies to identify genomic factors associated with therapy resistance in castration resistant prostate cancer.

Arrays of High-Aspect Ratio Microchannels for High-Throughput Isolation of Circulating Tumor Cells (CTCs).

Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints

Cistrome analysis of YY1 uncovers a regulatory axis of YY1:BRD2/4-PFKP during tumorigenesis of advanced prostate cancer

Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series

Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases

Functional role for the c-Abl tyrosine kinase in meiosis I

Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps

Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium

Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.

Identification of a pseudogene that can masquerade as a mutant allele of the PTEN/MMAC1 tumor suppressor gene.

Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression ⬇️

Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.

Interaction between androgen receptor and coregulator SLIRP is regulated by Ack1 tyrosine kinase and androgen

Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability

Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer.

Mutation of androgen receptor N-terminal phosphorylation site Tyr-267 leads to inhibition of nuclear translocation and DNA binding

Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings

Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial

PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway.

Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer

Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy

Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancer.

Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC

Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment.

Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest.

Regulation of sensitivity to TRAIL by the PTEN tumor suppressor.

Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase

Renal cell carcinoma

Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer

Role for c-Abl tyrosine kinase in growth arrest response to DNA damage.

Signal transduction by wild-type and leukemogenic Abl proteins.

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.

The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels.

The impact of altered annexin I protein levels on apoptosis and signal transduction pathways in prostate cancer cells.

ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer

Zinc-induced PTEN protein degradation through the proteasome pathway in human airway epithelial cells.

c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency

p38 and EGF receptor kinase-mediated activation of the phosphatidylinositol 3-kinase/Akt pathway is required for Zn2+-induced cyclooxygenase-2 expression.